All In Biotech

Drug Trial Radar · NCT03407144

Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)

An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults With Newly Diagnosed Classical Hodgkin Lymphoma With Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667)

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

340

Planned (sponsor's estimate)

Start

Apr 9, 2018

Primary completion

Feb 12, 2027

Study completion Feb 12, 2027

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jan 23, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 3 years, up to 25 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will examine the safety and efficacy of pembrolizumab (MK-3475) in combination with chemotherapy in children and young adults with newly diagnosed classical Hodgkin Lymphoma (cHL) who are slow early responders (SERs) to frontline chemotherapy.

Conditions

  • Hodgkin Lymphoma

Interventions

  • pembrolizumabBiological

    2 mg/kg intravenous (IV) up to a max of 200 mg (3 to 17 years of age) or 200 mg IV (18 to 25 years of age); cycle frequency Q3W

  • doxorubicinDrug

    25 mg/m\^2 IV on Days 1 and 15 as part of ABVD induction therapy (cycle frequency: Q4W, Group 1) 40 mg/m\^2 IV on Days 1 and 15 as part of OEPA induction therapy (cycle frequency: Q4W, Group 2) 25 mg/m\^2 IV on Days 1 and 15 as part of AVD chemotherapy (cycle frequency: Q4W, Group 1)

  • vinblastineDrug

    6 mg/m\^2 IV on Days 1 and 15 as part of ABVD induction therapy (cycle frequency: Q4W, Group 1) 6 mg/m\^2 IV on Days 1 and 15 as part of AVD chemotherapy (cycle frequency: Q4W, Group 1)

  • dacarbazineDrug

    375 mg/m\^2 IV on Days 1 and 15 as part of ABVD induction therapy (cycle frequency: Q4W, Group 1) 375 mg/m\^2 IV on Days 1 and 15 as part of AVD chemotherapy (cycle frequency: Q4W, Group 1) 250 mg/m\^2 IV on Days 1 to 3 as part of COPDAC-28 chemotherapy (cycle frequency: Q4W, Group 2)

  • cyclophosphamideDrug

    500 mg/m\^2 IV on days 1 and 8 as part of COPDAC-28 chemotherapy (cycle frequency: Q4W, Group 2)

  • vincristineDrug

    1.5 mg/m\^2 IV with maximum single dose 2 mg on Days 1, 8, and 15 as part of OEPA induction therapy (cycle frequency: Q4W, Group 2) 1.5 mg/m\^2 IV with maximum single dose 2 mg on Days 1 and 8 as part of COPDAC-28 chemotherapy (cycle frequency: Q4W, Group 2)

  • prednisone/prednisoloneDrug

    60 mg/m\^2/day orally divided in 3 doses on Days 1 to 15 as part of OEPA induction therapy (cycle frequency: Q4W, Group 2) 40 mg/m\^2/day orally divided in 3 doses on Days 1 to 15 as part of COPDAC-28 chemotherapy (cycle frequency: Q4W, Group 2)

  • bleomycinDrug

    10 units/m\^2 IV on Days 1 and 15 as part of ABVD induction therapy (cycle frequency: Q4W, Group 1)

  • etoposideDrug

    125 mg/m\^2 IV on Days 1 to 5 as part of OEPA induction therapy (cycle frequency: Q4W, Group 2)

  • Radiotherapy (RT)Radiation

    RT administered daily, dose dependent on randomization group and disease response.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) in SER Participants By Risk Group (Low, High) as Assessed by Blinded Independent Central Review (BICR)Time frame: Up to approximately 8 years

Locations

93 sites in 16 countries. Site status is shown where the registry gives one.

  • Children's Hospital of Alabama ( Site 0023)

    Birmingham, Alabama

  • Phoenix Childrens Hospital ( Site 0034)

    Phoenix, Arizona

  • Arkansas Children's Hospital ( Site 0046)

    Little Rock, Arkansas

  • Kaiser - Orange County ( Site 0084)

    Anaheim, California

  • Kaiser Permanente ( Site 0082)

    Downey, California

  • Kaiser - Fontana ( Site 0083)

    Fontana, California

  • MemorialCare Health System - Long Beach Medical Center-Cherese Mari Laulhere Children's Village ( Si

    Long Beach, California

  • Kaiser Permanente Downey Medical Center ( Site 0024)

    Los Angeles, California

  • Kaiser Permanente - Oakland ( Site 0047)

    Oakland, California

  • Kaiser Permanente - Roseville ( Site 0080)

    Roseville, California

  • Kaiser Permanente - Santa Clara ( Site 0079)

    Santa Clara, California

  • Children's Hospital - Colorado ( Site 0028)

    Aurora, Colorado

  • Connecticut Children's Medical Center ( Site 0045)

    Hartford, Connecticut

  • Yale Cancer Center ( Site 0061)

    New Haven, Connecticut

  • Children's National Medical Center ( Site 0090)

    Washington D.C., District of Columbia

  • University of Florida ( Site 0051)

    Gainesville, Florida

  • Memorial Regional Hospital/Joe DiMaggio Children's Hospital ( Site 0048)

    Hollywood, Florida

  • Arnold Palmer Hospital ( Site 0065)

    Orlando, Florida

  • Children's Healthcare of Atlanta at Egleston ( Site 0033)

    Atlanta, Georgia

  • University of Chicago ( Site 0066)

    Chicago, Illinois

  • Riley Hospital for Children ( Site 0091)

    Indianapolis, Indiana

  • University of Kentucky Markey Cancer Center ( Site 0057)

    Lexington, Kentucky

  • University of Louisville-Norton Children's Hospital ( Site 0059)

    Louisville, Kentucky

  • Johns Hopkins University ( Site 0025)

    Baltimore, Maryland

  • Children's Hospital of Michigan ( Site 0056)

    Detroit, Michigan

  • Karmanos Cancer Institute ( Site 0002)

    Detroit, Michigan

  • Children's Hospitals and Clinics of Minnesota ( Site 0036)

    Minneapolis, Minnesota

  • St. Louis Children's Hospital ( Site 0038)

    St Louis, Missouri

  • Alliance for Childhood Diseases ( Site 0064)

    Las Vegas, Nevada

  • Hackensack University Medical Center ( Site 0026)

    Hackensack, New Jersey

  • Rutgers Cancer Institute of New Jersey ( Site 0027)

    New Brunswick, New Jersey

  • Roswell Park Cancer Institute ( Site 0040)

    Buffalo, New York

  • Cohen Children's Medical Center of New York ( Site 0052)

    New Hyde Park, New York

  • Columbia University/Herbert Irving Cancer Center ( Site 0063)

    New York, New York

  • Memorial Sloan Kettering Cancer Center ( Site 0060)

    New York, New York

  • Weill Cornell Medicine ( Site 0032)

    New York, New York

  • UNC Lineberger Comprehensive Cancer ( Site 0044)

    Chapel Hill, North Carolina

  • Cincinnati Children's Hospital Medical Center ( Site 0035)

    Cincinnati, Ohio

  • Nationwide Children's Hospital ( Site 0037)

    Columbus, Ohio

  • St. Francis Hospital Cancer Center ( Site 0001)

    Greenville, South Carolina

Showing 40 of 93 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.